Skip to main content
SpringerLink
Log in

Inhibition of RIP2/RICK/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase (MAPK) have been used extensively in vitro and in vivo to investigate the role of p38 in physiological processes. As with other pharmacological inhibitors, non-specific targets of the p38 inhibitors have been reported. We have found that the protein kinase receptor interacting protein-2 (RIP2) is another target for the family of p38 inhibitors. The autophosphorylation of RIP2 was inhibited in vitro by the p38 inhibitors SB220025, SB203580 and PD169316 at concentrations comparable to those used to inhibit p38. We also identified two new in vitro substrates for RIP2, myelin basic protein and histone H3 with apparent K m values of 2.1 μM and 0.65 μM, respectively. The ability of RIP2 to phosphorylate these two substrates was sensitive to the p38 inhibitors as well. As was shown for p38α, a conserved threonine in the kinase domain of RIP2 is required for sensitivity to the inhibitors, indicating that the mechanism of inhibition of RIP2 is similar to that of p38. These results demonstrate that the pyridinyl imidazole inhibitors block RIP2 as well as p38 kinase activity. (Mol Cell Biochem 268: 129–140, 2005)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Frevel MA, Bakheet T, Silva AM, Hissong JG, Khabar KS, Williams BR: p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol Cell Biol 23: 425–436, 2003

    Article  Google Scholar 

  2. Dong C, Davis RJ, Flavell RA: Signaling by the JNK group of MAP kinases. c-jun N-terminal Kinase. J Clin Immunol 21: 253–257, 2001

    Google Scholar 

  3. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Keys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739–746, 1994

    Article  Google Scholar 

  4. Clerk A, Sugden PH: The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett 426: 93–96, 1998

    Article  Google Scholar 

  5. Lali FV, Hunt AE, Turner SJ, Foxwell BM: The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 275: 7395–7402, 2000

    Article  CAS  PubMed  Google Scholar 

  6. Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS, Graves LM: Inhibition of nucleoside transport by p38 MAPK inhibitors. J Biol Chem 277: 28364–28367, 2002

    Article  Google Scholar 

  7. Borsch-Haubold AG, Pasquet S, Watson SP: Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 273: 28766–28772, 1998

    Google Scholar 

  8. Hall-Jackson CA, Goedert M, Hedge P, Cohen P: Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 18: 2047–2054, 1999

    Article  Google Scholar 

  9. Kalmes A, Deou J, Clowes AW, Daum G: Raf-1 is activated by the p38 mitogen-activated protein kinase inhibitor, SB203580. FEBS Lett 444: 71–74, 1999

    Article  Google Scholar 

  10. LoGrasso PV, Frantz B, Rolando AM, O’Keefe SJ, Hermes JD, O’Neill EA: Kinetic mechanism for p38 MAP kinase. Biochemistry 36: 10422–10427, 1997

    Article  Google Scholar 

  11. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL, Lee JC: Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 272: 12116–12121, 1997

    Article  CAS  PubMed  Google Scholar 

  12. Lisnock J, Tebben A, Frantz B, O’Neill EA, Croft G, O’Keefe SJ, Li B, Hacker C, de Laszlo S, Smith A, Libby B, Liverton N, Hermes J, LoGrasso P: Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 37: 16573–16581, 1998

    Article  Google Scholar 

  13. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL, Goldsmith EJ: Structural basis of inhibitor selectivity in MAP kinases. Structure 6: 1117–1128, 1998

    Google Scholar 

  14. Wilson KP, McCaffrey PG, Hsiao K, Pazhanisamy S, Galullo V, Bemis GW, Fitzgibbon MJ, Caron PR, Murcko MA, Su MS: The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 4: 423–431, 1997

    Google Scholar 

  15. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M: Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol 5: 321–328, 1998

    Google Scholar 

  16. Gum RJ, McLaughlin MM, Kumar S, Wang Z, Bower MJ, Lee JC, Adams JL, Livi GP, Goldsmith EJ, Young PR: Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 273: 15605–15610, 1998

    Google Scholar 

  17. Inohara N, del Peso L, Koseki T, Chen S, Nunez G: RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis. J Biol Chem 273: 12296–12300, 1998

    Google Scholar 

  18. McCarthy JV, Ni J, Dixit VM: RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J Biol Chem 273: 16968–16975, 1998

    CAS  PubMed  Google Scholar 

  19. Thome M, Hofmann K, Burns K, Martinon F, Bodmer JL, Mattmann C, Tschopp J: Identification of CARDIAK, a RIP-like kinase that associates with caspase-1. Curr Biol 8: 885–888, 1998

    Google Scholar 

  20. Humke EW, Shriver SK, Starovasnik MA, Fairbrother WJ, Dixit VM: ICEBERG: A novel inhibitor of interleukin-1beta generation. Cell 103: 99–111, 2000

    Google Scholar 

  21. Navas TA, Baldwin DT, Stewart TA: RIP2 is a Raf1-activated mitogen-activated protein kinase kinase. J Biol Chem 274: 33684–33690, 1999

    Google Scholar 

  22. Stehlik C, Hayashi H, Pio F, Godzik A, Reed JC: CARD6 is a modulator of NF-kappa B activation by Nod1- and Cardiak-mediated pathways. J Biol Chem 278: 31941–31949, 2003

    Google Scholar 

  23. Chin AI, Dempsey PW, Bruhn K, Miller JF, Xu Y, Cheng G: Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature 416: 190–194, 2002

    CAS  PubMed  Google Scholar 

  24. Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, Janeway CA, Medzhitov R, Flavell RA: RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416: 194–199, 2002

    CAS  PubMed  Google Scholar 

  25. Wu JC, Merlino G, Fausto N: Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci USA 91: 674–678, 1994

    Google Scholar 

  26. Webb EC, Dixon M: Enzymes. New York, Academic Press Inc, 1997

    Google Scholar 

  27. Gallagher TF, Seibel GL, Kassis S, Laydon JT, Blumenthal MJ, Lee JC, Lee D, Boehm JC, Fier-Thompson SM, Abt JW, Soreson ME, Smietana JM, Hall RF, Garigipati RS, Bender PE, Erhard KF, Krog AJ, Hofmann GA, Sheldrake PL, McDonnell PC, Kumar S, Young PR, Adams JL: Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem 5: 49–64, 1997

    Google Scholar 

  28. Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD: Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 284: 687–692, 1998

    Google Scholar 

  29. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95–105, 2000

    Article  CAS  PubMed  Google Scholar 

  30. Beyaert R, Cuenda A, Vanden Berghe W, Plaisance S, Lee JC, Haegeman G, Cohen P, Fiers W: The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. Embo J 15: 1914–1923, 1996

    Google Scholar 

  31. Lisnock J, Tebben A, Frantz B, O’Neill EA, Croft G, O’Keefe SJ, Li B, Hacker C, de Laszlo S, Smith A, Libby B, Liverton N, Hermes J, LoGrasso P: Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 37: 16573–16581, 1998

    Article  Google Scholar 

  32. Meylan E, Martinon F, Thome M, Gschwendt M, Tschopp J: RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis. EMBO Rep 3: 1201–1208, 2002

    Google Scholar 

  33. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H: An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 100: 15434–15439, 2003

    Google Scholar 

  34. Eyers PA, van den IP, Quinlan RA, Goedert M, Cohen P: Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett 451: 191–196, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry and Biochemistry, University of Colorado at Boulder, Boulder, CO, USA

    Gretchen M. Argast

  2. Department of Pathology, University of Washington, Seattle, WA, USA

    Nelson Fausto & Jean S. Campbell

Authors
  1. Gretchen M. Argast
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nelson Fausto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean S. Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean S. Campbell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Argast, G.M., Fausto, N. & Campbell, J.S. Inhibition of RIP2/RICK/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK. Mol Cell Biochem 268, 129–140 (2005). https://doi.org/10.1007/s11010-005-3701-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-005-3701-0

Key words

Search

Navigation